Shein Shares Slide 9% in Hong Kong IPO Debut 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
GM Plans C$1.1 Billion Canada Investment Amid U.S. Tariff Pressure 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
Faraday Future Delivers First Robots in Middle East, Plans September Launches 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
Honda, Nissan Eye Shared Vehicle Software Platform by 2029 
South Korea Unveils Record $597 Billion 2027 Budget to Boost AI and Chips 
Pinterest Stock Falls as CFO Julia Brau Donnelly Resigns 
Trump Secures Drug Pricing Deals With Nine Pharma Companies 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
Apple’s Phil Schiller Steps Back as Leadership Shake-Up Accelerates 
The Realist’s Case: Lukas Kerrebijn of RD Dubai on the Narrative Dubai’s Agents Won’t Question 
Add as a preferred source on Google
SANTA MONICA, Calif., March 19, 2018 -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, announced today that Roger Crystal, MD., President and Chief Executive Officer, will provide a corporate overview at the Oppenheimer 28th Annual Healthcare Conference, being held March 20-21 at the Westin Grand Central Hotel in New York City.
| Presentation Details | ||
| Date: | Wednesday, March 21 | |
| Time: | 1:00pm Eastern Time | |
| Location: | Westin Grand Central Hotel, Track 3 | |
| Webcast: | https://ir.opiant.com | |
About Opiant Pharmaceuticals, Inc.
Opiant Pharmaceuticals, Inc. is a specialty pharmaceutical company developing pharmacological treatments for addictions. NIDA, a division of the NIH, describes these disorders as chronic relapsing brain diseases which burden society at both the individual and community levels. With its innovative opioid antagonist nasal delivery technology, Opiant is positioned to become a leader in these treatment markets. Its first product, NARCAN® Nasal Spray, is approved for marketing in the U.S. and Canada by the company’s partner, Adapt Pharma Operations Limited. For more information please visit: www.opiant.com.
CONTACTS:
Dan Ferry
Managing Director
LifeSci Advisors, LLC
[email protected]
(617) 535-7746
